Paul Tudor Jones’s Cabaletta Bio CABA Stock Holding History

Paul Tudor Jones’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$467K	Hold	150,000	–	–	﹤0.01%	2871
2026 Q1	$404K	Buy	+150,000	New	+$417K	﹤0.01%	2966

Other funds holding CABA

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Paul Tudor Jones's CABA Position: Q1 2025 in Review

Paul Tudor Jones sold out of Cabaletta Bio (CABA) in Q1 2025, closing a stake of 20,604 shares — an estimated $46.8K sold.

Paul Tudor Jones first reported a position in CABA in Q1 2024 and held it in 2 quarters. The position peaked at $364K in Q1 2024. 92 funds tracked by Wall St. Rank hold CABA as of Q1 2025.

Paul Tudor Jones reported no remaining Cabaletta Bio position as of Q1 2025 after selling out during the quarter.
Paul Tudor Jones sold 20,604 Cabaletta Bio shares in Q1 2025, an estimated $46.8K.
Paul Tudor Jones first reported a position in Cabaletta Bio in Q1 2024 and held it in 2 quarters.
Paul Tudor Jones's Cabaletta Bio position peaked at $364K in Q1 2024.
92 funds tracked by Wall St. Rank held Cabaletta Bio as of Q1 2025.

Based on Tudor Investment Corp's 13F filing for Q1 2025, filed 15 May 2025.